Operating Income (Loss) in USD of NKGen Biotech, Inc. from Q1 2021 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
NKGen Biotech, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q1 2021 to Q4 2024.
  • NKGen Biotech, Inc. Operating Income (Loss) for the quarter ending 31 Dec 2024 was -$5,100,000.000, a 45.9% increase year-over-year.
  • NKGen Biotech, Inc. Operating Income (Loss) for the twelve months ending 31 Dec 2024 was -$26,966,000.000, a 9.35% increase year-over-year.
  • NKGen Biotech, Inc. annual Operating Income (Loss) for 2024 was -$26,966,000.000, a 9.35% increase from 2023.
  • NKGen Biotech, Inc. annual Operating Income (Loss) for 2023 was -$29,746,000.000, a 22.2% decline from 2022.
  • NKGen Biotech, Inc. annual Operating Income (Loss) for 2022 was -$24,346,000.000, a 871% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

NKGen Biotech, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$26,966,000 -$5,100,000 +$4,334,000 +45.9% 01 Oct 2024 31 Dec 2024 10-K 08 Oct 2025
Q3 2024 -$31,300,000 -$6,788,000 +$115,000 +1.7% 01 Jul 2024 30 Sep 2024 10-Q 04 Mar 2025
Q2 2024 -$31,415,000 -$7,457,000 -$846,000 -12.8% 01 Apr 2024 30 Jun 2024 10-Q 12 Sep 2024
Q1 2024 -$30,569,000 -$7,621,000 -$823,000 -12.1% 01 Jan 2024 31 Mar 2024 10-Q 20 May 2024
Q4 2023 -$29,746,000 -$9,434,000 +$7,219,140 +43.4% 01 Oct 2023 31 Dec 2023 10-K 08 Oct 2025
Q3 2023 -$36,965,140 -$6,903,000 -$911,000 -15.2% 01 Jul 2023 30 Sep 2023 10-Q 04 Mar 2025
Q2 2023 -$36,054,140 -$6,611,000 -$5,642,048 -5.8% 01 Apr 2023 30 Jun 2023 10-Q 12 Sep 2024
Q1 2023 -$30,412,092 -$6,798,000 -$6,066,092 -8.3% 01 Jan 2023 31 Mar 2023 10-Q 20 May 2024
Q4 2022 -$24,346,000 -$16,653,140 -$15,247,050 -10.8% 01 Oct 2022 31 Dec 2022 10-K 16 Apr 2024
Q3 2022 -$9,098,950 -$5,992,000 -$5,187,951 -6.5% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 -$3,910,999 -$968,952 -$706,558 -2.7% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 -$3,204,441 -$731,908 -$696,234 -19.5% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q4 2021 -$2,508,207 -$1,406,090 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023
Q3 2021 -$804,049 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 -$262,394 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 -$35,674 28 Jan 2021 31 Mar 2021 10-Q 16 May 2022

NKGen Biotech, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$26,966,000 +$2,780,000 +9.3% 01 Jan 2024 31 Dec 2024 10-K 08 Oct 2025
2023 -$29,746,000 -$5,400,000 -22.2% 01 Jan 2023 31 Dec 2023 10-K 08 Oct 2025
2022 -$24,346,000 -$21,837,793 -8.7% 01 Jan 2022 31 Dec 2022 10-K 16 Apr 2024
2021 -$2,508,207 28 Jan 2021 31 Dec 2021 10-K 31 Mar 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.